Effect of Fluid Deresuscitation With Central Venous Pressure Target 0-4 mmHg in Septic Shock Pati… (NCT04156451) | Clinical Trial Compass
CompletedNot Applicable
Effect of Fluid Deresuscitation With Central Venous Pressure Target 0-4 mmHg in Septic Shock Patients
Indonesia44 participantsStarted 2019-11-14
Plain-language summary
A scientific research to prove the safety and effectiveness of TVS 0 - 4 mmHg as a target of resuscitation using furosemide, to improve Perfused Vessel Density (PVD) \> 25 mm / mm2, AKI stage (based on KDIGO criteria), CI \> 2.5 cc / min / m2 , prevent the incidence of intubation, reduce the duration of ventilator use \<120 hours and reduce the length of ICU stay in patients with septic shock after resuscitation
Who can participate
Age range
18 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Septic shock patients who meet the diagnosis criteria for quick SOFA and KDIGO 1 stage AKI (creatinine value 1.5 times OR creatinine value\> 0.3 initial OR urine production \<0.5 ml/kg/hour for 6-12 hours
* Patients, both men and women, in the age range of 18 - 60 years
* Patients who experience post clean operative sepsis
* Patients who agree to attend the study by signing informed consent
Exclusion Criteria:
* Patients with primary heart problems, right or heart failure suffer from congenital heart disease
* Have severe chronic obstructive pulmonary disease, patients with severe pleural effusion
* Patients who, based on ultrasound examination, found stones or tumors in the kidney during the study period
* CKD patients are based on history taking and physical examination
* DNR (do not resuscitate) patients
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial focused on 'fluid deresuscitation' — meaning removing excess fluids from the body after the initial septic shock treatment — can you explain whether that approach might be relevant to my situation, and how it differs from what I'd normally receive?
2The trial aimed for a very low central venous pressure target of 0–4 mmHg, which is quite different from standard care — what are the potential risks of maintaining such a low pressure target, and how would the medical team monitor me for complications?
3The primary outcome being measured was capillary perfusion density, which tracks blood flow to the tiniest vessels — what does this mean in practical terms for my recovery, and is there evidence this measurement predicts better outcomes in septic shock patients?
4Since this trial is already completed, are the results published or available, and if so, do they suggest this deresuscitation strategy was safe and beneficial enough to influence how you'd treat me?
5Is fluid deresuscitation with this kind of strict pressure target something that's already being used in standard practice, or would I only access it through a research setting — and what would my treatment look like if we don't pursue this approach?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.